Biotech | June 10, 2022
Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Bayer now present in four of the largest biotechnology hubs in the United States
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
States have an important role in ensuring food safety and healthy food practices.
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
AstraZeneca also played a critical role in the global response to COVID-19.
Subscribe To Our Newsletter & Stay Updated
